Physician profile
Barry A Lampl
NPI 1396749248
$5,136.47
in general payments reported to CMS, 2019-2025
21 companies · $802 in 2025
The $802 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $657 · 2021: $1,057 · 2022: $833 · 2023: $643 · 2024: $625 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,008 · Education: $61.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,008.31 |
| Education | $61.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,097.92 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $794.94 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Genentech USA, INC. | $534.18 | 2019-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $428.48 | 2019-2023 | Airduo Digihaler |
| Novartis Pharmaceuticals Corporation | $404.32 | 2019-2025 | |
| Optinose US, INC. | $385.52 | 2019-2025 | |
| Genzyme Corporation | $360.08 | 2019-2025 | |
| Amgen INC. | $317.89 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $220.48 | 2019-2023 | Dupixent |
| Kaleo, INC. | $147.13 | 2019-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $71.52 | 2021-2023 | |
| Ars Pharmaceuticals Operations, INC. | $70.93 | 2025 | Neffy |
| Greer Laboratories, INC. | $69.57 | 2019-2023 | Oralair |
| Jubilant Hollisterstier LLC | $56.16 | 2019-2024 | |
| Hikma Pharmaceuticals USA | $50.73 | 2021-2023 | Ryaltris |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $26.60 | 2025 | Alvesco |
| Uswm, LLC | $25.00 | 2021 | |
| Blueprint Medicines Corporation | $21.54 | 2023 | Ayvakit |
| Pfizer INC. | $20.77 | 2022 | |
| Eyevance Pharmaceuticals LLC | $16.91 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Lampl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.